EndoQuest, Focusing on Robot Technology, Receives $42 Million Investment

EndoQuest Robotics, a privately held medical device company and pioneering leader in the development of innovative endoluminal robotics technologies, announced the successful completion of a $42 million C-1 preferred financing round. This strategic financing will accelerate the advancement of its breakthrough flexible endoluminal robot, which aims to transform minimally invasive procedures. It was led by the company's former investors CE Ventures Limited and McNair Interests Ltd. and new investor Puma Venture Capital LLC. This significant investment reflects strong confidence in EndoQuest's vision to revolutionise endoluminal procedures through cutting-edge robotic technology. The newly acquired capital will be instrumental in driving key initiatives, including further research and development, regulatory milestones, commercialisation efforts and strengthening the company's leading position in flexible endoluminal robotics.

Also Read: Crait, Creating AI-Powered Visuals, Completes Pre-Seed Investment Round

EndoQuest

EndoQuest Robotics is focused on addressing unmet needs in gastrointestinal ("GI") and other endoluminal surgeries by developing an innovative robotic system that offers precision, flexibility and better patient outcomes. It is designed to navigate and perform procedures in luminal areas of the body, allowing minimally invasive interventions and enhancing the capabilities of healthcare professionals.